Moleculin Appoints Leading Expert in Pancreatic Cancer to its Scientific Advisory Board to Support Development of Annamycin Nov 4, 2024 08:30AM
Moleculin Biotech (MBRX) Completes End of Phase 2 Meeting with FDA for Annamycin in AML Jul 10, 2024 08:30AM
Moleculin Completes End of Phase 2 Meeting with FDA for Annamycin in AML Jul 10, 2024 08:30AM
Moleculin Biotech (MBRX) Announces Additional Positive Preliminary Interim Data from AML Clinical Trial Jun 14, 2024 08:00AM
Moleculin Announces Additional Positive Preliminary Interim Data from AML Clinical Trial Jun 14, 2024 08:00AM
View Older Stories

Jun 12, 2024 09:00AM Moleculin to Present at the Virtual Investor Pitch Conference
Jun 5, 2024 08:55AM Moleculin to Participate in the Virtual Investor Lunch Break Series
May 16, 2024 08:32AM Moleculin Abstract Accepted for Poster Presentation at the European Hematology Association (EHA) 2024 Hybrid Congress
May 15, 2024 08:38AM Moleculin Announces Commencement of NIH-Funded Phase 2 Clinical Trial of STAT3 Inhibitor for the Treatment of Glioblastoma (NU 21C06)
May 13, 2024 07:30AM Moleculin Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 9, 2024 08:32AM Moleculin Biotech (MBRX) Announces U.S. Patent Issue Notification for Lipid-Based Delivery Technology for Annamycin
May 9, 2024 08:30AM Moleculin Announces U.S. Patent Issue Notification for Lipid-Based Delivery Technology for Annamycin
May 8, 2024 08:45AM Moleculin to Report First Quarter 2024 Financial Results on May 10, 2024 and Host Conference Call and Webcast
May 7, 2024 08:55AM Moleculin Biotech (MBRX) Reports Higher AML Complete Remission (CR) Rates and Significant Durability with Additional Interim Subject Data
May 7, 2024 08:55AM Moleculin Reports Higher AML Complete Remission (CR) Rates and Significant Durability with Additional Interim Subject Data
May 2, 2024 09:00AM Moleculin to Host Virtual AML Clinical Day Featuring Internationally Renowned Clinician, Martin S. Tallman, MD, on May 7, 2024
May 1, 2024 08:50AM Moleculin Announces Formation of Scientific Advisory Board to Support Development of Annamycin
Apr 25, 2024 09:45AM Moleculin Biotech (NASDAQ:MBRX) Participates in Virtual Investor "What This Means" Segment Hosted by JTC Team
Apr 18, 2024 08:32AM Moleculin Biotech (MBRX) Announces EMA Grants Orphan Drug Designation for Treatment of Acute Myeloid Leukemia
Apr 18, 2024 08:30AM European Medicines Agency (EMA) Grants Orphan Drug Designation for Moleculin's Treatment of Acute Myeloid Leukemia (AML)
Apr 10, 2024 08:30AM Moleculin Announces Presentation of Positive Data Demonstrating High Anti-Cancer Activity of Annamycin and Non-Cardiotoxic Properties
Mar 28, 2024 10:45AM Moleculin to Present at the MedInvest Biotech & Pharma Investor Conference
Mar 27, 2024 09:25AM Moleculin to Participate in the Virtual Investor Lunch Break: The Moleculin Opportunity
Mar 27, 2024 09:05AM Moleculin Biotech (MBRX) Issues US Patent for Annamycin Targeting Unmet Need in AML
Mar 27, 2024 09:05AM Moleculin Announces U.S. Patent Issue Notification for Annamycin Targeting Unmet Need in AML
Mar 25, 2024 07:30AM Moleculin Biotech (MBRX) Reports Positive Interim Data in Annamycin MB-106 Phase 1B/2 AML Trial
Mar 25, 2024 07:30AM Moleculin Announces Positive Interim Data in Annamycin MB-106 Phase 1B/2 AML Trial
Mar 22, 2024 04:05PM Moleculin Reports Full Year 2023 Financial Results
Mar 20, 2024 07:30AM Moleculin to Report Full Year 2023 Financial Results on March 22, 2024 and Host Conference Call and Webcast
Mar 19, 2024 04:30PM Moleculin Biotech (MBRX) Announces 1:15 Reverse Share Split
Mar 19, 2024 04:30PM Moleculin Announces Reverse Stock Split
Mar 12, 2024 09:05AM Moleculin to Present at the 36th Annual ROTH Conference
Jan 24, 2024 08:50AM Moleculin Biotech (MBRX) Reports 2023 Year-End Annamycin Clinical Trials Preliminary Data
Jan 24, 2024 08:50AM Moleculin Announces 2023 Year-End Annamycin Clinical Trials Preliminary Data and 2024 Expectations for Multiple Data Readouts and Transition to Pivotal Phase 2B/3
Dec 11, 2023 08:51AM Moleculin Biotech (MBRX) Presents Positive Interim Data from Phase 1B/2 Clinical Trial in AML
Dec 11, 2023 08:50AM Moleculin Presents Positive Interim Data from Phase 1B/2 Clinical Trial in AML at Meeting with KOL's in Conjunction with ASH Annual Meeting
Nov 13, 2023 08:06AM Moleculin Biotech (MBRX) Reports Positive Interim Data in Annamycin Clinical Trials
Nov 13, 2023 08:05AM Moleculin Announces Positive Interim Data in Annamycin Clinical Trials: MB-106 AML Trial Complete Response (CR) Rate of 38% and MB-107 STS Lung Mets Trial Median Phase 1B Extended Overall Survival of
Nov 13, 2023 08:00AM Moleculin Reports Third Quarter 2023 Financial Results
Nov 7, 2023 08:45AM Moleculin to Report Third Quarter Financial Results on November 13, 2023 and Host Conference Call and Webcast
Nov 6, 2023 08:46AM Moleculin Biotech (MBRX) presents positive Phase 1B/2 clinical trial evaluating Annamycin
Nov 6, 2023 08:35AM Moleculin Presents Positive Preliminary Efficacy Findings from Phase 1B/2 Clinical Trial Demonstrating 64% Stable Disease Rate Through Two Cycles of Annamycin for the Treatment of Soft Tissue Sarcomas
Oct 11, 2023 09:05AM Moleculin to Participate in the Virtual Investor Ask the CEO Conference
Oct 2, 2023 08:40AM Moleculin Doses First Subjects in Phase 2 Portion of Clinical Trial Evaluating Annamycin in Combination with Cytarabine (Ara-C) for the Treatment of Acute Myeloid Leukemia (AML)
Sep 21, 2023 08:50AM Moleculin Announces Completion of Enrollment in U.S. Phase 1B/2 Clinical Trial Evaluating Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases (MB107)
Sep 18, 2023 08:40AM Moleculin Announces New Positive Independent Report of No Cardiotoxicity in Annamycin
Sep 14, 2023 08:35AM Moleculin Announces Abstract Accepted for Poster Presentation at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting
Sep 5, 2023 08:35AM Moleculin to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Aug 11, 2023 06:45AM Moleculin Reports Second Quarter 2023 Financial Results
Aug 10, 2023 04:07PM Moleculin Biotech (MBRX) Provides Update on Ongoing Clinical Trials and Outlines Expected Upcoming Milestones
Aug 10, 2023 04:05PM Moleculin Provides Update on Ongoing Clinical Trials and Outlines Expected Upcoming Milestones
Aug 7, 2023 08:40AM Moleculin Biotech (MBRX) Retains Shareholder Intelligence Services, LLC to Investigate Potential Naked Short Selling
Aug 7, 2023 08:40AM Moleculin Retains Shareholder Intelligence Services, LLC to Investigate Potential Naked Short Selling
Aug 3, 2023 08:45AM Moleculin to Report Second Quarter Financial Results on August 11, 2023 and Host Conference Call and Webcast
Jul 13, 2023 08:41AM Moleculin Biotech (MBRX) Announces Publication of Data from Successful European Phase 1 Trial of Annamycin
View Older Stories